Aktuellt
SENASTE
At SEB’s Nordic Seminar, we learned Fluoguide has decided to accelerate development of FG001 for photothermal therapy (PTT), as we hoped. Inevitably, this will result in a delay in pivotal study start, as we expected, but as we argued in our 13 Nov comment, it is a 'no-brainer'. Although details still need to be ironed out with the FDA and EMA, the decision strongly reinforces our confidence that mgmt takes sound, data-driven decisions that favour long-term value creation.
LÄS MER
